

Corrigenda and Addenda

Correction: The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis

João Estarreja^{1*}, PharmD; Priscila Mendes^{1*}, MSc, PharmD, PhD; Carina Silva^{1,2*}, BSc, MSc, PhD; Pedro Camacho^{1*}, BSc, MSc, PhD; Vanessa Mateus^{1,3*}, MSc, PharmD, PhD

¹Health & Technology Research Center, Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal

²Centro de Estatística e Aplicações, Universidade de Lisboa, Lisbon, Portugal

³iMed.Ulisboa, Faculdade de Farmacia, Universidade de Lisboa, Lisbon, Portugal

* all authors contributed equally

Corresponding Author:

Vanessa Mateus, MSc, PharmD, PhD
Health & Technology Research Center
Escola Superior de Tecnologia da Saúde
Instituto Politécnico de Lisboa
Avenida D João II
Lote 4.69.01
Lisbon, 1990-096
Portugal
Phone: 351 218980409
Email: vanessa.mateus@estesl.ipl.pt

Related Article:

Correction of: <https://www.researchprotocols.org/2023/1/e38658>

(*JMIR Res Protoc* 2023;12:e50411) doi: [10.2196/50411](https://doi.org/10.2196/50411)

In “The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis” (*JMIR Res Protoc* 2023;12:e38658) the authors noted a missing Acknowledgments section. The Acknowledgments section has now been added to the published paper as follows:

H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020.

The correction will appear in the online version of the paper on the JMIR Publications website on July 4, 2023, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.

This is a non-peer-reviewed article. Submitted 29.06.23; accepted 30.06.23; published 04.07.23.

Please cite as:

Estarreja J, Mendes P, Silva C, Camacho P, Mateus V

Correction: The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis

JMIR Res Protoc 2023;12:e50411

URL: <https://www.researchprotocols.org/2023/1/e50411>

doi: [10.2196/50411](https://doi.org/10.2196/50411)

PMID:

©João Estarreja, Priscila Mendes, Carina Silva, Pedro Camacho, Vanessa Mateus. Originally published in JMIR Research Protocols (<https://www.researchprotocols.org>), 04.07.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <https://www.researchprotocols.org>, as well as this copyright and license information must be included.